Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.16%
#3 Glidr Glidr +36.87%
#4 CoW Protocol CoW Protocol +36.53%
#5 RedStone RedStone +28.90%
#6 Humanity Humanity +26.35%
#7 Codatta Codatta +22.55%
#8 Walrus Walrus +19.98%
#9 The Black Bull The Black Bull +17.02%
#10 Enso Enso +16.70%
Coin of the day
EXOD EXOD
設定
言語
日本
通貨
USD
テーマ
Jupiter Neurosciences, Inc. Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc.

JUNS
株式のランク #36527
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in... Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
株価
$5.34
最終同期: 2026-08-14
時価総額
$2.59M
変化（1日）
-11.00%
変化（1年）
313.95%
国
US
取引 Jupiter Neurosciences, Inc. (JUNS)

カテゴリー

Healthcare
Jupiter Neurosciences, Inc.（JUNS）の収益
Aug 2026 時点の収益 TTM: 0
Jupiter Neurosciences, Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Jupiter Neurosciences, Inc. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE